Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for Brown Adipose Tissue Activation in Healthy Volunteers and PCOS
NCT03049462Phase 1Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Mar 2017
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirabegron in polycystic ovary syndrome (PCOS) (5 cohorts), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Change in BAT metabolic activity at 4 weeks and Change in insulin sensitivity at 4 weeks. Started Mar 2017; status: completed.
02
Drugs
mirabegron
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT03049462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049462.